open access

Vol 19, No 1 (2012)
Review paper
Published online: 2012-02-02
Get Citation

ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation?

Michał Tendera, Marcin Syzdół, Zofia Parma
Cardiol J 2012;19(1):4-10.

open access

Vol 19, No 1 (2012)
Review articles
Published online: 2012-02-02

Abstract

Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa — rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF. (Cardiol J 2012; 19, 1: 4–10)

Abstract

Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa — rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF. (Cardiol J 2012; 19, 1: 4–10)
Get Citation

Keywords

atrial fibrillation; stroke prevention; apixaban; dabigatran; rivaroxaban

About this article
Title

ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation?

Journal

Cardiology Journal

Issue

Vol 19, No 1 (2012)

Article type

Review paper

Pages

4-10

Published online

2012-02-02

Bibliographic record

Cardiol J 2012;19(1):4-10.

Keywords

atrial fibrillation
stroke prevention
apixaban
dabigatran
rivaroxaban

Authors

Michał Tendera
Marcin Syzdół
Zofia Parma

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl